International Clinical Trial: A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain

Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07465029) titled 'A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain' on Feb. 24.

Study Type: Observational

Primary Sponsor: Bristol-Myers Squibb

Condition: Lower-risk Myelodysplastic Syndromes (TD LR-MDS)

Intervention: Drug: Erythropoiesis-stimulating agents (ESAs) Biological: Luspatercept Drug: Lenalidomide Drug: Hypomethylating agents (HMAs)

Recruitment Status: Not recruiting

Date of First Enrollment: February 2, 2026

Target Sample Size: 1300

Countries of Recruitment: Spain

To know more, visit https://clinicaltrials.gov/study/NCT07465029

Publis...